A Multicentre, Double-Blind, Parallel Group Comparative Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone vs. Glibenclamide Therapy, When Administered to Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Phase 3
Extension study 49653/009 was conducted. An analysis-ready dataset and reporting and analysis plan are not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
July 2015